P K Konwloh1, C L Cambell1, S Ade2,3,4, P Bhat5, A D Harries2,6, E Wilkinson7, C T Cooper1. 1. National Leprosy & Tuberculosis Control Programme, Ministry of Health, Monrovia, Liberia. 2. International Union Against Tuberculosis and Lung Disease, Paris, France. 3. National Tuberculosis Control Programme, Cotonou, Benin. 4. Faculty of Medicine, University of Parakou, Parakou, Benin. 5. Ministry of Health, Government of Karnataka, Bangalore, India. 6. London School of Hygiene & Tropical Medicine, London, UK. 7. Institute of Medicine, University of Chester, Chester, UK.
Abstract
Setting: National Leprosy and Tuberculosis (TB) Control Programme, Liberia. Objectives: To assess TB case finding, including human immunodeficiency virus (HIV) associated interventions and treatment outcomes, before (January 2013-March 2014), during (April 2014-June 2015) and after (July-December 2015) the Ebola virus disease outbreak. Design: A cross-sectional study and retrospective cohort analysis of outcomes. Results: The mean quarterly numbers of individuals with presumptive TB and the proportion diagnosed as smear-positive were: pre-Ebola (n = 7032, 12%), Ebola (n = 6147, 10%) and post-Ebola (n = 6795, 8%). For all forms of TB, stratified by category and age group, there was a non-significant decrease in the number of cases from the pre-Ebola to the Ebola and post-Ebola periods. There were significant decreases in numbers of cases with smear-positive pulmonary TB (PTB) from the pre-Ebola period (n = 855), to the Ebola (n = 640, P < 0.001) and post-Ebola (n = 568, P < 0.001) periods. The proportions of patients tested for HIV, found to be HIV-positive and started on antiretroviral therapy decreased as follows: pre-Ebola (respectively 72%, 15% and 34%), Ebola (69%, 14% and 30%) and post-Ebola (68%, 12% and 26%). Treatment success rates among TB patients were: 80% pre-Ebola, 69% Ebola (P < 0.001) and 73% post-Ebola (P < 0.001). Loss to follow-up was the main contributing adverse outcome. Conclusion: The principal negative effects of Ebola were the significant decreases in diagnoses of smear-positive PTB, the declines in HIV testing and antiretroviral therapy uptake and poor treatment success. Ways to prevent these adverse effects from recurring in the event of another Ebola outbreak need to be found.
Setting: National Leprosy and Tuberculosis (TB) Control Programme, Liberia. Objectives: To assess TB case finding, including human immunodeficiency virus (HIV) associated interventions and treatment outcomes, before (January 2013-March 2014), during (April 2014-June 2015) and after (July-December 2015) the Ebola virus disease outbreak. Design: A cross-sectional study and retrospective cohort analysis of outcomes. Results: The mean quarterly numbers of individuals with presumptive TB and the proportion diagnosed as smear-positive were: pre-Ebola (n = 7032, 12%), Ebola (n = 6147, 10%) and post-Ebola (n = 6795, 8%). For all forms of TB, stratified by category and age group, there was a non-significant decrease in the number of cases from the pre-Ebola to the Ebola and post-Ebola periods. There were significant decreases in numbers of cases with smear-positive pulmonary TB (PTB) from the pre-Ebola period (n = 855), to the Ebola (n = 640, P < 0.001) and post-Ebola (n = 568, P < 0.001) periods. The proportions of patients tested for HIV, found to be HIV-positive and started on antiretroviral therapy decreased as follows: pre-Ebola (respectively 72%, 15% and 34%), Ebola (69%, 14% and 30%) and post-Ebola (68%, 12% and 26%). Treatment success rates among TB patients were: 80% pre-Ebola, 69% Ebola (P < 0.001) and 73% post-Ebola (P < 0.001). Loss to follow-up was the main contributing adverse outcome. Conclusion: The principal negative effects of Ebola were the significant decreases in diagnoses of smear-positive PTB, the declines in HIV testing and antiretroviral therapy uptake and poor treatment success. Ways to prevent these adverse effects from recurring in the event of another Ebola outbreak need to be found.
Authors: M Edginton; D Enarson; R Zachariah; T Reid; S Satyanarayana; K Bissell; S G Hinderaker; T Harries Journal: Public Health Action Date: 2012-03-21
Authors: Erik von Elm; Douglas G Altman; Matthias Egger; Stuart J Pocock; Peter C Gøtzsche; Jan P Vandenbroucke Journal: Lancet Date: 2007-10-20 Impact factor: 79.321
Authors: David Leuenberger; Jean Hebelamou; Stefan Strahm; Nathalie De Rekeneire; Eric Balestre; Gilles Wandeler; François Dabis Journal: AIDS Date: 2015-09-10 Impact factor: 4.177
Authors: Stephen D Lawn; Peter Mwaba; Matthew Bates; Amy Piatek; Heather Alexander; Ben J Marais; Luis E Cuevas; Timothy D McHugh; Lynn Zijenah; Nathan Kapata; Ibrahim Abubakar; Ruth McNerney; Michael Hoelscher; Ziad A Memish; Giovanni Battista Migliori; Peter Kim; Markus Maeurer; Marco Schito; Alimuddin Zumla Journal: Lancet Infect Dis Date: 2013-03-24 Impact factor: 25.071
Authors: Amitabh B Suthar; Marco A Vitoria; Jason M Nagata; Xavier Anglaret; Dorothy Mbori-Ngacha; Omar Sued; Jonathan E Kaplan; Meg C Doherty Journal: Lancet HIV Date: 2015-03-03 Impact factor: 12.767
Authors: Augustine Talumba Choko; Nicola Desmond; Emily L Webb; Kondwani Chavula; Sue Napierala-Mavedzenge; Charlotte A Gaydos; Simon D Makombe; Treza Chunda; S Bertel Squire; Neil French; Victor Mwapasa; Elizabeth L Corbett Journal: PLoS Med Date: 2011-10-04 Impact factor: 11.069
Authors: Kathryn M Hogan; Henry Saidu Bangura; Jing Li; Mohamed Akmed Salim Kamara; Jiafu Jiang; Michael E von Fricken Journal: Am J Trop Med Hyg Date: 2022-03-14 Impact factor: 3.707
Authors: Bradley H Wagenaar; Orvalho Augusto; Jason Beste; Stephen J Toomay; Eugene Wickett; Nelson Dunbar; Luke Bawo; Chea Sanford Wesseh Journal: PLoS Med Date: 2018-02-20 Impact factor: 11.069
Authors: Pruthu Thekkur; Kudakwashe C Takarinda; Collins Timire; Charles Sandy; Tsitsi Apollo; Ajay M V Kumar; Srinath Satyanarayana; Hemant D Shewade; Mohammed Khogali; Rony Zachariah; I D Rusen; Selma Dar Berger; Anthony D Harries Journal: Trop Med Infect Dis Date: 2021-05-31
Authors: Seid Getahun Abdela; Abel Balcha Berhanu; Leul Mesfin Ferede; Johan van Griensven Journal: Am J Trop Med Hyg Date: 2020-09 Impact factor: 2.345
Authors: Irene Mbithi; Pruthu Thekkur; Jeremiah Muhwa Chakaya; Elizabeth Onyango; Philip Owiti; Ngugi Catherine Njeri; Ajay M V Kumar; Srinath Satyanarayana; Hemant D Shewade; Mohammed Khogali; Rony Zachariah; I D Rusen; Selma Dar Berger; Anthony D Harries Journal: Trop Med Infect Dis Date: 2021-05-10